



EXPRESS SCRIPTS®

**Express Scripts, Inc.  
Pharmacy and Therapeutics Committee  
Proceedings  
March 15 and 16, 2008**

**New Drugs**

The Committee reviewed the following new drugs.

- A. Bystolic™ (nebivolol tablets)**
- B. Flector® Patch (diclofenac epolamine topical patch)**
- C. Veregen™ (sinecatechins ointment 15%)**
- D. Intelence™ (etravirine tablets)**
- E. Renvela® (sevelamer carbonate tablets)**
- F. Evamist™ (estradiol transdermal spray)**
- G. Emend® Injection (fosaprepitant dimeglumine for injection)**
- H. Arcalyst™ (riloncept for injection)**

**New Indications for Existing Products**

The Committee reviewed new indications for the following existing products: [See product inserts for specific wording.]

- A. WelChol® (colesevelam hydrochloride tablets)** - As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- B. Humira® (adalimumab injection)** - 1) Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. 2) Indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients aged 4 years and older. It can be used alone or in combination with methotrexate.
- C. Tysabri® (natalizumab injection)** - Treatment of moderate-to-severe Crohn's disease in patients with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn's disease therapies.
- D. Orencia® (abatacept injection)** - Expanded the indication to include inhibiting the progression of structural damage in patients with rheumatoid arthritis.
- E. Mycamine® (micafungin sodium for injection; IV infusion only)** - Treatment of patients with candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses. (Mycamine has not been adequately studied in patients with endocarditis, osteomyelitis and meningitis due to Candida).
- F. Asmanex® (mometasone furoate inhalation powder)** - The maintenance treatment of asthma as prophylactic therapy in children aged 4 to 11 years.
- G. Avastin® (bevacizumab) for injection** - For use in combination with paclitaxel for the treatment of patients who have not received chemotherapy for metastatic HER2-negative breast cancer. This indication is based on improvement in progression free survival.
- H. Janumet™ (sitagliptin/ metformin hydrochloride tablets)** - For use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin are appropriate.

- I. **Rituxan® (rituximab injection)** - Expanded the indication in rheumatoid arthritis to include and to slow the progression of structural damage.
- J. **Abilify™ and Abilify Discmelt™ (aripiprazole tablets, oral solution, intramuscular injection, and orally disintegrating tablets)** - the acute treatment of manic or mixed episodes associated with Bipolar Disorder with or without psychotic features in pediatric patients aged 10 to 17 years.
- K. **Nexium® (esomeprazole magnesium delayed-release oral suspension and delayed release capsules)** - Short-term treatment of gastroesophageal reflux disease (GERD) and healing of erosive esophagitis in pediatric patients aged 1 to 11 years of age.
- L. **Aloxi® (palonosetron hydrochloride injection)** - Prevention of postoperative nausea and vomiting for up to 24 hours following surgery; efficacy beyond 24 hours has not been demonstrated.

### **New Clinical Line Extensions**

The Committee reviewed new clinical line extensions for the following products.

- A. **Altace® (ramipril tablets)**
- B. **Tussicaps® (hydrocodone polistirex and chlorpheniramine polistirex extended-release capsules)**
- C. **Gammagard S/D (immune globulin intravenous [human] injection – IgA less than 1 µg/mL in 5% solution)**
- D. **Flo-Pred™ (prednisolone acetate oral suspension)**
- E. **Tekturna HCT™ (aliskiren hydrochlorothiazide tablets)**
- F. **Moxatag™ (amoxicillin extended-release tablets)**
- G. **Accretropin® (somatropin injection)**
- H. **Xyzal® (levocetirizine dihydrochloride oral solution)**
- I. **Simcor® (simvastatin/niacin extended-release tablets)**
- J. **Cosyntropin™ (alpha 1-24 corticotropin injection)**
- K. **Luvox® CR (fluvoxamine maleate extended-release capsules)**